Bernfeld P, Homburger F
J Natl Cancer Inst. 1976 Apr;56(4):741-7. doi: 10.1093/jnci/56.4.741.
The biologic activity of a smoking product other than tobacco (Cytrel) was compaed with that of an American-type blend of cigarette tobaccos by application of the smoke condensate (SC) to shaved mouse skin. In 4 nonsimultaneous experiments, SC's from the former were equivalent or lower in tumorigenicity than equal doses of those from the latter, studied simultaneously and under identical conditions; this was true for widely varying doses of SC's, ranging from 35 to 246 mg nonaqueous condensate (NAC) administered to each mouse/week for 63-92 weeks. The response to SC from smoking products other than tobacco ranged from a complete lack of epidermoid carcinomas and papillomas at the lower doses to an incidence of lesions in 25.3% of the animals at the highest dose. The SC from a typical American blend of tobaccos caused skin lesions in 18.7-39.1% of the animals. SC from type 324 Cytrel, applied at the even higher dose of 365 mg/mouse/week, caused papillomas or carcinomas in only 22.0% of the animals, as compared with 39.1% of mice after adminstration of 245 mg SC from the American blend of cigarette tobacco; this was the highest dose that could be achieved with a test material containing nicotine. SC from a 1:1 blend of Cytrel with cigarette tobacco produced considerably fewer skin lesions at the lower dose levels than did SC from tobacco. At the lowest dose of 35 mg/mouse/week, 2 and 18.7% of the animals had lesions, and at a 54-mg dose, 11.3 and 22.7% had lesions from the blend and tobacco samples, respectively. At an increased level (113 mg), the response was the same for the SC from a 1:1 blend and from cigarette tobacco. There existed an excellent dose-response relationship for SC from type 308 Cytrel tested at four dose levels: 8.4, 113, 246, and 383 mg NAC/mouse/week, with 0, 18.7, 25.3, and 57.7% of the animals exhibiting skin lesions, respectively. Based on the criteria inherent in the technique of "mouse skin painting", Cytrel variants appeared to be lower or equal in tumorigenicity than did cigarette tobacco.
通过将烟浓缩物(SC)涂抹于剃毛的小鼠皮肤上,对一种非烟草吸烟产品(赛翠尔)的生物活性与美国混合型卷烟烟草的生物活性进行了比较。在4个非同时进行的实验中,在相同条件下同时研究发现,前者的SC在致瘤性方面等同于或低于后者相同剂量的SC;对于广泛变化的SC剂量而言都是如此,即每周给每只小鼠施用35至246毫克非水浓缩物(NAC),持续63 - 92周。非烟草吸烟产品的SC所产生的反应范围为:低剂量时完全没有表皮样癌和乳头状瘤,高剂量时25.3%的动物出现病变。典型美国混合型烟草的SC使18.7% - 39.1%的动物出现皮肤病变。324型赛翠尔的SC以更高剂量365毫克/小鼠/周施用时,仅22.0%的动物出现乳头状瘤或癌,相比之下,施用美国混合型卷烟烟草的245毫克SC后有39.1%的小鼠出现病变;这是含尼古丁测试材料所能达到的最高剂量。赛翠尔与卷烟烟草1:1混合的SC在较低剂量水平时产生的皮肤病变明显少于烟草的SC。在最低剂量35毫克/小鼠/周时,混合样本和烟草样本分别有2%和18.7%的动物出现病变;在54毫克剂量时,分别有11.3%和22.7%的动物出现病变。在剂量增加到113毫克时,赛翠尔与卷烟烟草1:1混合的SC和卷烟烟草SC产生的反应相同。对308型赛翠尔的SC在四个剂量水平(8.4、113、246和383毫克NAC/小鼠/周)进行测试时,存在良好的剂量 - 反应关系,分别有0、18.7、25.3和57.7%的动物出现皮肤病变。根据“小鼠皮肤涂抹”技术所固有的标准,赛翠尔变体在致瘤性方面似乎低于或等同于卷烟烟草。